The DOI matches its Crossref record; 196 of the 196 references it cites were found in a registry or an index.
DPP4 in diabetes
Open accessAbstract
Dipeptidyl-peptidase 4 (DPP4) is a glycoprotein of 110 kDa, which is ubiquitously expressed on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal dipeptides from a variety of substrates, including cytokines, growth factors, neuropeptides, and the incretin hormones. Expression of DPP4 is substantially dysregulated in a variety of disease states including inflammation, cancer, obesity, and diabetes. Since the incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP), are major regulators of post-prandial insulin secretion, inhibition of DPP4 by the gliptin family of drugs has gained considerable interest for the therapy of type 2 diabetic patients. In this review, we summarize the current knowledge on the DPP4-incretin axis and evaluate most recent findings on DPP4 inhibitors. Furthermore, DPP4 as a type II transmembrane protein is also known to be cleaved from the cell membrane involving different metalloproteases in a cell-type-specific manner. Circulating, soluble DPP4 has been identified as a new adipokine, which exerts both para- and endocrine effects. Recently, a novel receptor for soluble DPP4 has been identified, and data are accumulating that the adipokine-related effects of DPP4 may play an important role in the pathogenesis of cardiovascular disease. Importantly, circulating DPP4 is augmented in obese and type 2 diabetic subjects, and it may represent a molecular link between obesity and vascular dysfunction. A critical evaluation of the impact of circulating DPP4 is presented, and the potential role of DPP4 inhibition at this level is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Colman (2022) · doi:10.1073/pnas · Cited by 4,370
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Bataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Obesity, Metabolic Syndrome, and Cardiovascular Disease
Grundy, S. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0372 · Cited by 1,371
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010) · Hepatology · doi:10.1002/hep.23594 · Cited by 1,336
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“Indeed, mRNA transcripts of the GLP-1R have been detected in the heart of rodents (185, 186) and humans (187).”
BackgroundLambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“However, in patientswith heart failure, pilot studies also suggest cardioprotection by GLP-1 infusion (196, 197).”
BackgroundVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
Lamers, D., Famulla, S., Wronkowitz, N., Hartwig, S., Lehr, S., Ouwens, D. M., Eckardt, K., Kaufman, J. M., Ryden, M., Müller, S., et al. (2011) · Diabetes · doi:10.2337/db10-1707 · Cited by 582
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Scanlan, M. J., Raj, B. K., Calvo, B., Garin-Chesa, P., Sanz-Moncasi, M. P., Healey, J. H., Old, L. J., & Rettig, W. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5657 · Cited by 574
Drug Design, Development and Therapy
(2020) · Drug Design Development and Therapy · doi:10.2147/dddt · Cited by 558
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.-M., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J., & Wagtmann, N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120069197 · Cited by 538
Mu, J., Woods, J., Zhou, Y.-P., Roy, R. S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A. D., et al. (2006) · Diabetes · doi:10.2337/db05-1602 · Cited by 449
Inflamed Adipose Tissue: A Culprit Underlying the Metabolic Syndrome and Atherosclerosis
Gustafson, B., Hammarstedt, A., Andersson, C. X., & Smith, U. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.147835 · Cited by 436
A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-?-naphthylamide
Hopsu-Havu, V. K., & Glenner, G. G. (1966) · Histochemie · doi:10.1007/bf00577838 · Cited by 435
Shah, Z., Kampfrath, T., Deiuliis, J. A., Zhong, J., Pineda, C., Ying, Z., Xu, X., Lu, B., Moffatt-Bruce, S., Durairaj, R., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.041418 · Cited by 377
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
Conarello, S. L., Li, Z., Ronan, J., Roy, R. S., Zhu, L., Jiang, G., Liu, F., Woods, J., Zycband, E., Moller, D. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0631828100 · Cited by 347
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346
Chou, E., Suzuma, I., Way, K. J., Opland, D., Clermont, A. C., Naruse, K., Suzuma, K., Bowling, N. L., Vlahos, C. J., Aiello, L. P., et al. (2002) · Circulation · doi:10.1161/hc0302.102143 · Cited by 337
Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders
GORRELL, M. D. (2005) · Clinical Science · doi:10.1042/cs20040302 · Cited by 334
Fadini, G. P., Boscaro, E., Albiero, M., Menegazzo, L., Frison, V., de Kreutzenberg, S., Agostini, C., Tiengo, A., & Avogaro, A. (2010) · Diabetes Care · doi:10.2337/dc10-0187 · Cited by 318
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
Nabeno, M., Akahoshi, F., Kishida, H., Miyaguchi, I., Tanaka, Y., Ishii, S., & Kadowaki, T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.010 · Cited by 310
Engel, M., Hoffmann, T., Wagner, L., Wermann, M., Heiser, U., Kiefersauer, R., Huber, R., Bode, W., Demuth, H.-U., & Brandstetter, H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230620100 · Cited by 305
Zaruba, M.-M., Theiss, H. D., Vallaster, M., Mehl, U., Brunner, S., David, R., Fischer, R., Krieg, L., Hirsch, E., Huber, B., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.013 · Cited by 301
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
Kitade, H., Sawamoto, K., Nagashimada, M., Inoue, H., Yamamoto, Y., Sai, Y., Takamura, T., Yamamoto, H., Miyamoto, K.-I., Ginsberg, H. N., et al. (2012) · Diabetes · doi:10.2337/db11-1506 · Cited by 292
Yoon, Y.-S., Uchida, S., Masuo, O., Cejna, M., Park, J.-S., Gwon, H.-C., Kirchmair, R., Bahlman, F., Walter, D., Curry, C., et al. (2005) · Circulation · doi:10.1161/01.cir.0000162472.52990.36 · Cited by 288
Matsubara, J., Sugiyama, S., Sugamura, K., Nakamura, T., Fujiwara, Y., Akiyama, E., Kurokawa, H., Nozaki, T., Ohba, K., Konishi, M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.07.053 · Cited by 273
Lambeir, A.-M., Proost, P., Durinx, C., Bal, G., Senten, K., Augustyns, K., Scharpé, S., Van Damme, J., & De Meester, I. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103106200 · Cited by 271
Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation.
Jin, X., Shepherd, R. K., Duling, B. R., & Linden, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119833 · Cited by 251
Best, J. H., Hoogwerf, B. J., Herman, W. H., Pelletier, E. M., Smith, D. B., Wenten, M., & Hussein, M. A. (2011) · Diabetes Care · doi:10.2337/dc10-1393 · Cited by 251
Shirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., et al. (2011) · Diabetes · doi:10.2337/db10-1338 · Cited by 246
Pacheco, R., Martinez-Navio, J. M., Lejeune, M., Climent, N., Oliva, H., Gatell, J. M., Gallart, T., Mallol, J., Lluis, C., & Franco, R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501050102 · Cited by 243
Sitagliptin Exerts an Antinflammatory Action
Makdissi, A., Ghanim, H., Vora, M., Green, K., Abuaysheh, S., Chaudhuri, A., Dhindsa, S., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1544 · Cited by 241
Erdogdu, Ö., Nathanson, D., Sjöholm, Å., Nyström, T., & Zhang, Q. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.022 · Cited by 229
Adipose Dipeptidyl Peptidase-4 and Obesity
Sell, H., Blüher, M., Klöting, N., Schlich, R., Willems, M., Ruppe, F., Knoefel, W. T., Dietrich, A., Fielding, B. A., Arner, P., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0496 · Cited by 218
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Fadini, G. P., & Avogaro, A. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.05.001 · Cited by 213
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities and Differences
Baetta, R., & Corsini, A. (2011) · Drugs · doi:10.2165/11591400-000000000-00000 · Cited by 209
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Nauck, M. A. (2013) · Diabetes Care · doi:10.2337/dc12-2504 · Cited by 205
On the origin of serum CD26 and its altered concentration in cancer patients
Cordero, O. J., Salgado, F. J., & Nogueira, M. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0728-1 · Cited by 198
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes
Pratley, R. E., & Salsali, A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x162746 · Cited by 195
Circulating CD26 Is Negatively Associated with Inflammation in Human and Experimental Arthritis
Busso, N., Wagtmann, N., Herling, C., Chobaz-Péclat, V., Bischof-Delaloye, A., So, A., & Grouzmann, E. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62266-3 · Cited by 191
Dipeptidyl-Peptidase IV Converts Intact B-Type Natriuretic Peptide into Its des-SerPro Form
Brandt, I., Lambeir, A.-M., Ketelslegers, J.-M., Vanderheyden, M., Scharpé, S., & De Meester, I. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.057638 · Cited by 189
Eltzschig, H. K., Faigle, M., Knapp, S., Karhausen, J., Ibla, J., Rosenberger, P., Odegard, K. C., Laussen, P. C., Thompson, L. F., & Colgan, S. P. (2006) · Blood · doi:10.1182/blood-2006-02-001016 · Cited by 188
Nonalcoholic fatty liver disease
Krawczyk, M., Bonfrate, L., & Portincasa, P. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2010.08.005 · Cited by 187
Yang, L., Di, G., Qi, X., Qu, M., Wang, Y., Duan, H., Danielson, P., Xie, L., & Zhou, Q. (2014) · Diabetes · doi:10.2337/db14-0163 · Cited by 184
The Role of Metformin in the Management of NAFLD
Mazza, A., Fruci, B., Garinis, G. A., Giuliano, S., Malaguarnera, R., & Belfiore, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/716404 · Cited by 184
Matsushita, K., Blecker, S., Pazin-Filho, A., Bertoni, A., Chang, P. P., Coresh, J., & Selvin, E. (2010) · Diabetes · doi:10.2337/db10-0165 · Cited by 183
Piazza, G. A., Callanan, H. M., Mowery, J., & Hixson, D. C. (1989) · Biochemical Journal · doi:10.1042/bj2620327 · Cited by 178
Dipeptidyl peptidase-4: A key player in chronic liver disease
Itou, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i15.2298 · Cited by 177
Zhong, J., Rao, X., Deiuliis, J., Braunstein, Z., Narula, V., Hazey, J., Mikami, D., Needleman, B., Satoskar, A. R., & Rajagopalan, S. (2013) · Diabetes · doi:10.2337/db12-0230 · Cited by 176
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
Palazzuoli, A. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5789 · Cited by 172
A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase.
Morrison, M. E., Vijayasaradhi, S., Engelstein, D., Albino, A. P., & Houghton, A. N. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.4.1135 · Cited by 170
Badeanlou, L., Furlan-Freguia, C., Yang, G., Ruf, W., & Samad, F. (2011) · Nature Medicine · doi:10.1038/nm.2461 · Cited by 168
Ervinna, N., Mita, T., Yasunari, E., Azuma, K., Tanaka, R., Fujimura, S., Sukmawati, D., Nomiyama, T., Kanazawa, A., Kawamori, R., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1855 · Cited by 167
Dobrian, A. D., Ma, Q., Lindsay, J. W., Leone, K. A., Ma, K., Coben, J., Galkina, E. V., & Nadler, J. L. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00463.2010 · Cited by 166 · cited 1×
“Furthermore, sitagliptin was shown to have potent anti-inflammatory properties by suppressing expression of pro-inflammatory genes in mouse and humans (98, 99).”
BackgroundBiftu, T., Sinha-Roy, R., Chen, P., Qian, X., Feng, D., Kuethe, J. T., Scapin, G., Gao, Y. D., Yan, Y., Krueger, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401992e · Cited by 166
Ghersi, G., Zhao, Q., Salamone, M., Yeh, Y., Zucker, S., & Chen, W.-T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1245 · Cited by 166
Ishibashi, Y., Matsui, T., Maeda, S., Higashimoto, Y., & Yamagishi, S.-I. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-125 · Cited by 165
The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
Avogaro, A., & Fadini, G. P. (2014) · Diabetes Care · doi:10.2337/dc14-0865 · Cited by 164
Shigeta, T., Aoyama, M., Bando, Y. K., Monji, A., Mitsui, T., Takatsu, M., Cheng, X.-W., Okumura, T., Hirashiki, A., Nagata, K., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.096479 · Cited by 163
Gautier, J., Fetita, S., Sobngwi, E., & Salaün-Martin, C. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70190-8 · Cited by 163
Wronkowitz, N., Görgens, S. W., Romacho, T., Villalobos, L. A., Sánchez‐Ferrer, C. F., Peiró, C., Sell, H., & Eckel, J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.004 · Cited by 159
Association of Systemic Chemokine Concentrations With Impaired Glucose Tolerance and Type 2 Diabetes
Herder, C., Haastert, B., Müller-Scholze, S., Koenig, W., Thorand, B., Holle, R., Wichmann, H.-E., Scherbaum, W. A., Martin, S., & Kolb, H. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s11 · Cited by 158
Ye, Y., Keyes, K. T., Zhang, C., Perez-Polo, J. R., Lin, Y., & Birnbaum, Y. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00867.2009 · Cited by 157
Röhrborn, D., Eckel, J., & Sell, H. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.08.029 · Cited by 151
Self-citationThe Cysteine-Rich Region of Dipeptidyl Peptidase IV (CD 26) Is the Collagen Binding Site
Löster, K., Zeilinger, K., Schuppan, D., & Reutter, W. G. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2782 · Cited by 143
Scheen, A. J. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.642866 · Cited by 140
Kaji, K., Yoshiji, H., Ikenaka, Y., Noguchi, R., Aihara, Y., Douhara, A., Moriya, K., Kawaratani, H., Shirai, Y., Yoshii, J., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0783-4 · Cited by 139
Miyazaki, M. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.707 · Cited by 137
dos SANTOS, L., Salles, T. A., Arruda-Junior, D. F., Campos, L. C. G., Pereira, A. C., Barreto, A. L. T., Antônio, E. L., Mansur, A. J., Tucci, P. J. F., Krieger, J. E., et al. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000057 · Cited by 136
Ceriello, A., Esposito, K., Testa, R., Bonfigli, A. R., Marra, M., & Giugliano, D. (2011) · Diabetes Care · doi:10.2337/dc10-1949 · Cited by 134
A Novel Consensus Motif in Fibronectin Mediates Dipeptidyl Peptidase IV Adhesion and Metastasis
Cheng, H.-C., Abdel‐Ghany, M., & Pauli, B. U. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303424200 · Cited by 133
Yano, T., Liu, Z., Donovan, J., Thomas, M. K., & Habener, J. F. (2007) · Diabetes · doi:10.2337/db07-0291 · Cited by 132
Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.
Yilmaz, Y. N., Yönal, O., Deyneli, O., Çelikel, Ç., Kalaycı, C., & Duman, D. (2012) · PubMed · Cited by 131
Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Guo, J., & Friedman, S. L. (2007) · Seminars in Liver Disease · doi:10.1055/s-2007-991517 · Cited by 129
CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1
Ohnuma, K., Yamochi, T., Uchiyama, M., Nishibashi, K., Yoshikawa, N., Shimizu, N., Iwata, S., Tanaka, H., Dang, N. H., & Morimoto, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405266101 · Cited by 126
Takeda, Y., Fujita, Y., Honjo, J., Yanagimachi, T., Sakagami, H., Takiyama, Y., Makino, Y., Abiko, A., Kieffer, T. J., & Haneda, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2365-4 · Cited by 126
Dipeptidyl peptidase IV (DDP IV) in NASH patients
Balaban, Y. H., Korkusuz, P., Simsek, H., Gokcan, H., Gedikoglu, G., Pinar, A., Hascelik, G., Asan, E., Hamaloglu, E., & Tatar, G. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31905-2 · Cited by 125
Iwasaki, T., Yoneda, M., Inamori, M., Shirakawa, J., Higurashi, T., Maeda, S., Terauchi, Y., & Nakajima, A. (2011) · Hepatogastroenterology · doi:10.5754/hge11263 · Cited by 124
Forssmann, U., Stoetzer, C., Stephan, M., Kruschinski, C., Skripuletz, T., Schade, J., Schmiedl, A., Pabst, R., Wagner, L., Hoffmann, T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.1120 · Cited by 123
Ikushima, H., Munakata, Y., Ishii, T., Iwata, S., Terashima, M., Tanaka, H., Schlossman, S. F., & Morimoto, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8439 · Cited by 123
Firneisz, G., Varga, T., Lengyel, G., Fehér, J., Ghyczy, D., Wichmann, B., Selmeci, L., Tulassay, Z., Rácz, K., & Somogyi, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012226 · Cited by 121 · cited 1×
“Similarly, in patients with NAFLD, DPP4 activity in serum correlates with markers of liver damage, such as serum gamma-glutamyltranspeptidase and ALT levels, but do not correlate with fasting blood glucose levels and HbA1c values (156, 157).”
BackgroundEndothelial actions of atrial and B‐type natriuretic peptides
Kühn, M. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01827.x · Cited by 121
Abbott, C. A., McCaughan, G. W., & Gorrell, M. D. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01166-7 · Cited by 120
Lim, J., Iyer, A., Liu, L., Suen, J. Y., Lohman, R., Seow, V., Yau, M., Brown, L., & Fairlie, D. P. (2013) · The FASEB Journal · doi:10.1096/fj.13-232702 · Cited by 118
Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
Kern, M., Klöting, N., Niessen, H. G., Thomas, L. H., Stiller, D., Mark, M., Klein, T., & Blüher, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038744 · Cited by 117
Goto, H., Nomiyama, T., Mita, T., Yasunari, E., Azuma, K., Komiya, K., Arakawa, M., Jin, W. L., Kanazawa, A., Kawamori, R., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.131 · Cited by 116
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Aroor, A. R., Sowers, J. R., Jia, G., & DeMarco, V. G. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00209.2014 · Cited by 116
Hoffmann, T., Faust, J., Neubert, K., & ANSORGE, S. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81609-4 · Cited by 115
Åhrén, B., & Hughes, T. E. (2004) · Endocrinology · doi:10.1210/en.2004-1174 · Cited by 111
Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice
Mentzel, S., Dijkman, H. B., Van Son, J. P., Koene, R. A., & Assmann, K. J. (1996) · Journal of Histochemistry & Cytochemistry · doi:10.1177/44.5.8627002 · Cited by 108
Shah, P., Ardestani, A. D., Dharmadhikari, G., Laue, S., Schumann, D., Kerr-Conte, J. A., Pattou, F. N., Klein, T., & Maedler, K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1029 · Cited by 108
Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia–reperfusion injury
Chinda, K., Palee, S., Surinkaew, S., Phimphilai, M., Chattipakorn, S. C., & Chattipakorn, N. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.01.011 · Cited by 103
Peptide YY: more than just an appetite regulator
Persaud, S. J., & Bewick, G. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3292-y · Cited by 102
D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1135 · Cited by 99
Rask, E., Olsson, T., Söderberg, S., Holst, J. J., Tura, A., Pacini, G., & Åhrén, B. (2004) · Metabolism · doi:10.1016/j.metabol.2003.11.011 · Cited by 99
Des-serine-proline brain natriuretic peptide 3–32 in cardiorenal regulation
Boerrigter, G., Costello‐Boerrigter, L. C., Harty, G. J., Lapp, H., & Burnett, J. C. J. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00569.2006 · Cited by 99
Yan, S., Marguet, D., Dobers, J., Reutter, W. G., & Fan, H. (2003) · European Journal of Immunology · doi:10.1002/eji.200323469 · Cited by 97
Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo.
Ahmad, S., Wang, L., & Ward, P. E. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11437-7 · Cited by 95
Mari, A., Scherbaum, W. A., Nilsson, P. M., Lalanne, G., Schweizer, A., Dunning, B. E., Jauffret, S., & Foley, J. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1639 · Cited by 92
Kirino, Y., Sato, Y., Kamimoto, T., Kawazoe, K., Minakuchi, K., & Nakahori, Y. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0424 · Cited by 91
Böhm, S. K., Gum, J. R., Erickson, R. H., Hicks, J. W., & Kim, Y. S. (1995) · Biochemical Journal · doi:10.1042/bj3110835 · Cited by 89
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Giugliano, D., Sportiello, L., Capuano, A., Maiorino, M., Rossi, F., & Esposito, K. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s37647 · Cited by 86
Distribution of GLP‐1 and PACAP receptors in human tissues
Wei, Y., & Mojsov, S. (1996) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.1996.42256000.x · Cited by 86
Omar, B. A., Liu, L., Yamada, Y., Seino, Y., Marchetti, P., & Åhrén, B. (2014) · Diabetologia · doi:10.1007/s00125-014-3299-4 · Cited by 84
Foley, J. E., Bunck, M. C., Möller-Goede, D. L., Poelma, M., Nijpels, G., Eekhoff, E. M., Schweizer, A., Heine, R. J., & Diamant, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2167-8 · Cited by 83 · cited 1×
“Treatment with vildagliptin over a longer period of time could also confirm an increased β-cell function in humans as a result of improved sensitivity of β cells to glucose (140, 141).”
BackgroundDPP‐IV inhibition enhances the antilipolytic action of NPY in human adipose tissue
Kos, K., Baker, A. R., Jernås, M., Harte, A. L., Clapham, J. C., O’Hare, J. P., Carlsson, L. M. S., Kumar, S., & McTernan, P. G. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00909.x · Cited by 83
Fan, H., Meng, W., Kilian, C., Grams, S., & Reutter, W. G. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00243.x · Cited by 81
Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells
Pala, L., Mannucci, E., Pezzatini, A., Ciani, S., Sardi, J., Raimondi, L., Ognibene, A., Cappadona, A., Vannelli, B., & Rotella, C. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.111 · Cited by 79
Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells
Bauvois, B., Djavaheri‐Mergny, M., Rouillard, D., Dumont, J., & Wietzerbin, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203292 · Cited by 74
Maiztegui, B., Borelli, M. I., Madrid, V., Zotto, H. H. D., Raschia, M. A., Francini, F., Massa, M. L., Flores, L. E., Rebolledo, O. R., & Gagliardino, J. J. (2010) · Clinical Science · doi:10.1042/cs20100372 · Cited by 73
The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats
Duttaroy, A., Voelker, F. A., Merriam, K., Zhang, X., Ren, X., Subramanian, K., Hughes, T. E., & Burkey, B. F. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.062 · Cited by 73
Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
Ito, H., Nishio, S., & Abe, M. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s54679 · Cited by 72
Engel, M., Hoffmann, T., Manhart, S., Heiser, U. F., Chambre, S., Huber, R., Demuth, H., & Bode, W. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.11.014 · Cited by 72
Klein, T., Fujii, M., Sandel, J. P., Shibazaki, Y., Wakamatsu, K., Mark, M., & Yoneyama, H. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0053-9 · Cited by 71
Ikushima, H., Munakata, Y., Iwata, S., Ohnuma, K., Kobayashi, S., Dang, N. H., & Morimoto, C. (2002) · Cellular Immunology · doi:10.1016/s0008-8749(02)00010-2 · Cited by 70
Stonehouse, A. H., Darsow, T., & Maggs, D. G. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00143.x · Cited by 69
Trelagliptin: First Global Approval
McKeage, K. (2015) · Drugs · doi:10.1007/s40265-015-0431-9 · Cited by 68
Chang, G., Zhang, P., Ye, L., Lü, K., Wang, Y., Duan, Q., Zheng, A., Qin, S., & Zhang, D. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.007 · Cited by 67
Liu, Q., Adams, L. A., Broyde, A., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-32 · Cited by 66
Ku, H.-C., Chen, W., & Su, M. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0665-3 · Cited by 65
Yu, D. M. T., Slaitini, L., Gysbers, V., Riekhoff, A. G. M., Kähne, T., Knott, H. M., Meester, I. D., Abbott, C. A., McCaughan, G. W., & Gorrell, M. D. (2010) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2010.02488.x · Cited by 64
Shinjo, T., Nakatsu, Y., Iwashita, M., Sano, T., Sakoda, H., Ishihara, H., Kushiyama, A., Fujishiro, M., Fukushima, T., Tsuchiya, Y., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00553.2014 · Cited by 64
Karl, T., Hoffmann, T., Pabst, R., & von Hörsten, S. (2003) · Physiology & Behavior · doi:10.1016/s0031-9384(03)00229-4 · Cited by 63
Baturcam, E., Abubaker, J. A., Tiss, A., Abu‐Farha, M., Khadir, A., Al-Ghimlas, F., Al‐Khairi, I., Cherian, P., Elkum, N. B., Hammad, M. M., et al. (2014) · Mediators of Inflammation · doi:10.1155/2014/627150 · Cited by 61
Segers, V. F. M., Revin, V., Wu, W., Qiu, H., Yan, Z., Lee, R. T., & Sandrasagra, A. (2011) · Circulation · doi:10.1161/circulationaha.110.991786 · Cited by 60
Lessard, J., Pelletier, M., Biertho, L. D., Biron, S., Marceau, S., Hould, F., Lebel, S., Moustarah, F., Lescelleur, O., Marceau, P., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122065 · Cited by 59
Neumiller, J. J. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.013 · Cited by 59
Turcot, V., Bouchard, L., Faucher, G., Tchernof, A., Deshaies, Y., Përusse, L., Bélisle, A., Marceau, S., Biron, S., Lescelleur, O., et al. (2010) · Obesity · doi:10.1038/oby.2010.198 · Cited by 56
Yasuda, N., Nagakura, T., Yamazaki, K., Inoue, T., & Tanaka, I. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)01637-5 · Cited by 56
Lee, J.-G., Kang, D. G., Yu, J. R., Kim, Y. R., Kim, J. S., Koh, G. P., & Lee, D. H. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.2.149 · Cited by 56
Bouchard, L., Faucher, G., Tchernof, A., Deshaies, Y., Lebel, S., Hould, F., Marceau, P., & Vohl, M. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0049-4 · Cited by 53
Adenosine effects upon insulin action on lipolysis and glucose transport in human adipocytes
Heseltine, L., Webster, J. M., & Taylor, R. (1995) · Molecular and Cellular Biochemistry · doi:10.1007/bf00944394 · Cited by 51
Shimasaki, T., Masaki, T., Mitsutomi, K., Ueno, D., Gotoh, K., Chiba, S., Kakuma, T., & Yoshimatsu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063626 · Cited by 51
Fukuda-Tsuru, S., Kakimoto, T., Utsumi, H., Kiuchi, S., & Ishii, S. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.030 · Cited by 50
Therapeutic vaccine against DPP4 improves glucose metabolism in mice
Pang, Z., Nakagami, H., Osako, M. K., Koriyama, H., Nakagami, F., Tomioka, H., Shimamura, M., Kurinami, H., Takami, Y., Morishita, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322009111 · Cited by 50
Altered Zonal Expression of the Cd26 Antigen (Dipeptidyl Peptidase Iv) in Human Cirrhotic Liver
Matsumoto, Y., Bishop, A. G., & McCaughan, G. W. (1992) · Hepatology · doi:10.1002/hep.1840150613 · Cited by 49
Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction.
Schrader, W. P., West, C. A., Miczek, A. D., & Norton, E. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30659-2 · Cited by 47
Pancreatic Beta Cells Synthesize Neuropeptide Y and Can Rapidly Release Peptide Co-Transmitters
Whim, M. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019478 · Cited by 46
Frerker, N., Raber, K. A., Bode, F. J., Skripuletz, T., Nave, H., Klemann, C., Pabst, R., Stephan, M., Schade, J., Brabant, G. E., et al. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.064 · Cited by 45
Furuta, S., Smart, C., Hackett, A., Benning, R. K., & Warrington, S. (2012) · Xenobiotica · doi:10.3109/00498254.2012.731618 · Cited by 41
Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression
Rosmaninho‐Salgado, J., Marques, A. P., Estrada, M. F., Santana, M. M., Cortez, V., Grouzmann, E., & Cavadas, C. (2012) · Peptides · doi:10.1016/j.peptides.2012.06.014 · Cited by 40
Teneligliptin: expectations for its pleiotropic action
Morishita, R., & Nakagami, H. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1000301 · Cited by 39
Smith, R. E., Talhouk, J. W., BROWN, E. E., & Edgar, S. E. (1998) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1998.14.851 · Cited by 38
Akarte, A. S., Srinivasan, B. P., & Gandhi, S. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.03.013 · Cited by 38
Karagiannides, I., Bakirtzi, K., Kokkotou, E. G., Stavrakis, D. G., Margolis, K. G., Thomou, T., Giorgadze, N., Kirkland, J. L., & Pothoulakis, C. (2011) · Endocrinology · doi:10.1210/en.2011-1170 · Cited by 38
Wang, T., Gou, Z., Wang, F., Ma, M., & Zhai, S.-D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103798 · Cited by 37
Leibowitz, G., Cahn, A., Bhatt, D. L., Hirshberg, B., Mosenzon, O., Wei, C., Jermendy, G., Sheu, W. H., Sendon, J. L., Im, K., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12445 · Cited by 37
Green, B., Irwin, N., & Flatt, P. R. (2006) · Peptides · doi:10.1016/j.peptides.2005.11.010 · Cited by 37
Incretin-based therapies for obesity treatment
de Mello, A. H., Prá, M. D., Cardoso, L. C., Schraiber, R. D. B., & Rezin, G. T. (2015) · Metabolism · doi:10.1016/j.metabol.2015.05.012 · Cited by 36
Significance of CXCL12 in Type 2 Diabetes Mellitus and Its Associated Complications
Karimabad, M. N., & Hassanshahi, G. (2014) · Inflammation · doi:10.1007/s10753-014-9981-3 · Cited by 36
Aghili, N., Devaney, J. M., Alderman, L. O., Żukowska, Z., Epstein, S. E., & Burnett, M. S. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.10.001 · Cited by 36
Effects of Sitagliptin on Nonalcoholic Fatty Liver Disease in Diet-Induced Obese Rats
Beysel, S., Değertekin, C. K., Yılmaz, G., Çakır, N., Arslan, M., & Törüner, F. B. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0128 · Cited by 36
DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus
Sugimoto, T. (2014) · Medical Science Monitor · doi:10.12659/msm.890989 · Cited by 34
Gu, N., Tsuda, M., Matsunaga, T., Adachi, T., Yasuda, K., Ishihara, A., & Tsuda, K. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.05015.x · Cited by 33
Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets
Liu, L., Omar, B. A., Marchetti, P., & Åhrén, B. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.096 · Cited by 33
Åkesson, L., Åhrén, B., Manganiello, V. C., Holst, L. S., Edgren, G., & Degerman, E. (2003) · Endocrinology · doi:10.1210/en.2003-0364 · Cited by 33
Fu, J. Q., LIU, B. C. L., Liu, P., Liu, L., Li, G., Wu, B., & Liu, X. (2010) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0030-1261965 · Cited by 32
Tariq, M., Masoud, M. S., Mehmood, A., Khan, S. N., & Riazuddin, S. A. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-115 · Cited by 31
MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis inob/obmice
Ohyama, T., Sato, K., Yamazaki, Y., Hashizume, H., Horiguchi, N., Kakizaki, S., Mori, M., Kusano, M., & Yamada, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.16227 · Cited by 31
Itou, M., Kawaguchi, T., Taniguchi, E., Oriishi, T., & Sata, M. (2012) · Case Reports in Gastroenterology · doi:10.1159/000341510 · Cited by 30
Canneva, F., Golub, Y., Distler, J. H. W., Dobner, J., Meyer, S., & von Hörsten, S. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.01.007 · Cited by 30
Ben‐Shlomo, S., Zvibel, I., Varol, C., Spektor, L., Shlomai, A., Santo, E. M., Halpern, Z., Oren, R., & Fishman, S. (2013) · Obesity · doi:10.1002/oby.20340 · Cited by 28
Sato, Y., Koshioka, S., Kirino, Y., Kamimoto, T., Kawazoe, K., Abe, S., Minakuchi, K., & Nakahori, Y. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.10.019 · Cited by 28
Pais, R., Zietek, T., Hauner, H., Daniel, H., & Skurk, T. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00329.2013 · Cited by 27
Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure?
Bhatt, D. L., & Cavender, M. A. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.05.005 · Cited by 26
Han, S. J., Choi, S., KANG, Y. Y., Jung, J. G., Yi, S., Kim, H. J., Lee, K. W., & Kim, D. J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.01.016 · Cited by 24
Rizos, E. C., Ntzani, E., Παπάνας, Ν., Tsimihodimos, V., Mitrogianni, Z., Maltezos, E. S., & Elisaf, M. (2013) · Current Vascular Pharmacology · doi:10.2174/15701611113119990103 · Cited by 21
Turcot, V., Tchernof, A., Deshaies, Y., Përusse, L., Bélisle, A., Marceau, P., Hould, F., Lebel, S., & Vohl, M. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-4 · Cited by 20
Shlomo, S. B., Zvibel, I., Rabinowich, L., Goldiner, I., Shlomai, A., Santo, E. M., Halpern, Z., Oren, R., & Fishman, S. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2353-7 · Cited by 19
Stephan, M., Radicke, A., Leutloff, S., Schmiedl, A., Pabst, R., von Hörsten, S., Dettmer, S., Lotz, J., & Nave, H. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.09.024 · Cited by 14
on behalf of the EpiDREAM and INTERHEART investigators, Bailey, S. D., Xie, C., Paré, G., Montpetit, A., Mohan, V., Yusuf, S., Gerstein, H. C., Engert, J. C., & Anand, S. S. (2013) · Diabetologia · doi:10.1007/s00125-013-3142-3 · Cited by 13
Aghili, N., Devaney, J. M., Li, M., Reilly, M. P., Rader, D. J., Żukowska, Z., Burnett, M. S., & Epstein, S. E. (2012) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(12)61401-6 · Cited by 13
Nilius, R., Stuhec, K., & Dietrich, R. A. (1991) · PubMed · Cited by 13
Insulinotropin PACAP Potentiates Insulin Action: Stimulation of Glucose Uptake in 3T3‐LI Adipocytes
Yada, T., Nakata, M., & Shioda, S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb07018.x · Cited by 11
Ommen, E. S., Xu, L., O’Neill, E. A., Goldstein, B. J., Kaufman, K. D., & Engel, S. S. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0098-y · Cited by 10
Clinical audit of patients using DPP4 inhibitors in longstanding type 2 diabetes
Kumar, K. V. S. H., & Gupta, A. (2014) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2014.04.031 · Cited by 9
DPP-4 inhibitor des-F-sitagliptin treatment increased insulin exocytosis from db/db mice β cells
Nagamatsu, S., Ohara‐Imaizumi, M., Nakamichi, Y., Aoyagi, K., & Nishiwaki, C. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.119 · Cited by 8
Chung, K., Huang, C., Cheng, J., Tsai, C.-H., Suen, C., Hwang, M., & Chen, X. (2011) · Biochemistry · doi:10.1021/bi200605h · Cited by 7
Focosi, D., Kast, R. E., Galimberti, S., & Petrini, M. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0208109 · Cited by 7
Cited by
Bajaj, V., Gadi, N., Spihlman, A. P., Wu, S. C., Choi, C. H., & Moulton, V. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.571416 · Cited by 476
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
Klemann, C., Wagner, L., Stephan, M., & von Hörsten, S. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12781 · Cited by 425
Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications
Ren, J., Wu, N. N., Wang, S., Sowers, J. R., & Zhang, Y. (2021) · Physiological Reviews · doi:10.1152/physrev.00030.2020 · Cited by 370
Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031094 · Cited by 328
Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication
Funcke, J.-B., & Scherer, P. E. (2019) · Journal of Lipid Research · doi:10.1194/jlr.r094060 · Cited by 327
Metadata
- Authors
- Röhrborn, D.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2015
- Volume
- 6
- Pages
- 386-386
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W1507910610
- Cited by
- 440
- References
- 196
- FWCI
- 22.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.